![](https://investorshub.advfn.com/uicon/430424.png?cb=1554906782)
Friday, December 23, 2022 6:23:41 PM
As some of us discussed on the board back in the day, Dr. V’s trial was never blinded. They knew how to test for Methylation status and idh-1 status back then, but a huge chunk of the patients in the trial were undetermined or not tested in the status log. In other words, by todays standards, many did not have GBM (and had a much more favorable prognosis) and a huge proportion may have been methylated mgmt (a more favorable prognosis)
It was the equivalent of a phase ii trial because it had so many flaws. Phase two unblinded trials often have great results. After 20 years of the Stupp protocol, we know from many trials and real world data that long term survival is nearly nonexistent. We know Temodar interferes with tumor cell repair in methylated patients but that this is not durable. We also know Temodar in standard doses unfortunately exhaust T-cells and these are two of many reasons why its usage does not stop the nearly universal fatal prognosis for GBM.
I recently glanced at Dr. V’s critique of the Phase iii DCVax-l results. My first impression is that his apparent demand for a second phase iii trial is irresponsible and illogical. This is an orphan designated indication where the FDA required a crossover because his Stupp protocol trial therapy as now implemented is an eventual death sentence by itself. The phase iii trial for DCVax-l, unlike his old trial, was blinded during randomization and thereafter. When it became obvious PFS could not be used as an accurate endpoint due to pseudo progression, the trial remained blinded but was converted to utilize a concurrent ECA. The blinded trial tested for idh1 and methylation status. Unlike his unblinded trial, the DCVax-l trial was not padded. The trial resulted in unprecedented actual long term survival — not extrapolated.
Anyway, I’ll look at his paper further to address his other thoughts, but right now it’s Christmas.
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM